Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beijing Shenogen Pharma Group Ltd.

Latest From Beijing Shenogen Pharma Group Ltd.

China Investment Roundup: Spotlight On Oncology

Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.

BioPharmaceutical China

Shenogen’s Icaritin: A New First-Line Therapy For HCC?

Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.

BioPharmaceutical China

Asia Spotlight: China’s First TCM Law Excites Industry Looking For Cheer

A long-awaited new law that could greatly enlarge the market for traditional Chinese medicines has prompted domestic drug makers in China to race to develop new products, but could it also hurt multinational drug companies in the country?

BioPharmaceutical China

China Sows Ground For TCM Market Growth With Regulatory Framework

A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.

Consumer BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Shenogen Pharma Group
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Beijing Shenogen Pharma Group Ltd.
  • Senior Management
  • Kun Meng, PhD, CEO
    Charlie Wang, PhD, CSO
    Jun Bao, PhD, SVP, CBO
    Hong Guo, MD, VP, Clin. Dev. & CMO
  • Contact Info
  • Beijing Shenogen Pharma Group Ltd.
    Phone: 10 80709213
    29 Life Science Park Rd.
    Ste. 101 Bldg B
    Beijing, 102206